Medical comms - Today Stories

London, United Kingdom, Tuesday 10 March - George Health, a profit-for-purpose company, today announces £27 million / $35 million of new financing to accelerate the commercialisation of affordable drug treatments and technologies for some of the world’s biggest killers. This funding round was led by Bupa Australia, Federation Asset Management and the Australian Government-backed Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF), managed by Brandon Capital Partners. The investments are set to fast-track the growth of George Health Enterprises, the commercial arm of the world-leading George Institute for Global Health, and George Medicines, its late-stage drug development company. George Health Enterprises will receive almost £17 million from Federation Asset Man…

– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma – – Transaction Supports Gilead’s Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline – FOSTER CITY, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and…

CROMSOURCE announced today the achievement of a significant milestone in the digital management of clinical research projects for their clients. In February 2020 CROMSOURCE initiated the 1000th trial to be managed within the advanced TheClinical digital environment. TheClinical, developed by Techorizon, consists of customisable, integrated modules dedicated to the efficient digital management of every aspect of clinical research and development projects. ‘Digitalisation is a key foundation of our working philosophy, and has been a significant source of our investment for many years’, commented CROMSOURCE CEO, Dr. Oriana Zerbini. ‘Our adoption and development of digital technologies provides our clients with benefits in efficiency, quality and visibility on their projects.’ ‘Our clients typ…

The Office for Life Sciences announces Harwell as one of six new designated Zones in the UK - the only one in Oxfordshire/ Thames Valley Thursday 20th February, Harwell, Oxfordshire: Announced today by the Office for Life Sciences, Harwell Science and Innovation Campus has been designated as a Life Sciences Opportunity Zone, which is awarded for a 10-year period. Harwell, already a world-renowned science and technology campus, is now one of only seven locations in the UK [six announced today], and the only one in Oxfordshire / Thames Valley, to hold the title. With this status secured, Harwell’s Life Sciences capabilities will continue to grow as the announcement further underscores the role of the Campus as a national hub for health and Life Sciences research, and a launch platform for co…

The Wuhan coronavirus outbreak shows no signs of slowing down, and developments in the unfolding story are so rapid that it can be difficult keep track of them. GlobalData’s Pharmaceutical Technology team have produced a free-to-access dashboard to keep industry, media, and the public, up-to-date with the latest developments in the coronavirus outbreak and a range of tools to provide key information. The dashboard contains: Breaking news and regional reports Maps and trackers of confirmed cases, global spread, deaths and recoveries Timeline of events from the first cases to the latest news Social media tracking analysing trending keywords, hashtags, mentioned companies and countries An FAQ resource answering common questions Click on the link below to visit the web page. https://www.phar…

Both Edwards Lifesciences and Teva won four Golds and one Silver each, making them joint top of the pharma charts. Roche won two Golds and two Silvers and Reckitt Benckiser (RB) two Golds. Other Gold winners on the client side included ALK, Heart UK, Immunocore, Janssen, Mundipharma, Novo Nordisk and Santen.    The event is the largest in the industry awards calendar and attracts around 900 people from across pharma companies and agencies to the largest ballroom in Park Lane. The ceremony was skilfully hosted by Claudia Winkleman in combination with comedian Zoe Lyons and everyone’s favourite voice, Alan Dedicoat, the voice of Strictly.  Although the Gold Awards were dominated by Havas Lynx Group and VCCP, there were 21 different agencies and 30 different pharmaceutical or healthcare organ…

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry. Patrick Aiyes, Senior Immunology Analyst at leading data and analytics company GlobalData, observes the key trends that has shaped the immunology market in the last decade: Key immunology drugs “The immunology market has seen a continuous increase in the sales of interleukin inhibitors and a decrease in the sales of TNF inhibitors - primarily because of the entry of biosimilars into the market and the increased safety profile associated with interleukin inhibitors. Abbvie’s Humira will end the decade as the highest grossing drug of 2019, generating sales of approximately $19bn globally, while Janssen’s Stelara will be the highest-grossing i…

Following the news that sepsis has been found to be a bigger killer than cancer worldwide in a study by Rudd et al; Kasey Fu, Director of Epidermiology at GlobalData, provides her view: “The *7MM will see diagnosed incident cases of sepsis grow at an annual growth rate (AGR) of 2.06% per year over the next ten years from 2.5 million cases in 2016 to 3.1 million in 2026. By these estimations, this year will see around 600,000 cases of septic shock and close to three million cases of intensive care unit (ICU) hospitalized sepsis.  “The study by Rudd et al, published in Lancet, was an impressive and enormous undertaking. Looking at the study's robust and comprehensive methodology, it is not surprising that sepsis incidence was found to be twice as what was known previously. Compared to most…

Fasenra being evaluated in eight eosinophil-driven diseases beyond severe asthma AstraZeneca today announced three new trials for Fasenra (benralizumab) in skin diseases, adding to five trials already underway for the medicine in eosinophil-driven diseases (EDDs) beyond severe asthma. In EDD, immune system dysfunction causes eosinophil recruitment and activation leading to chronic local and/or systemic inflammation.1 The three new trials for Fasenra in skin diseases include two Phase II trials to assess the potential of the medicine in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU); and a Phase III trial in bullous pemphigoid (BP). Five additional Phase III clinical trials are underway to investigate the potential of Fasenra in: Disease Trial name Estimated data readout …

Ashfield Pharmacovigilance Inc. becomes part of Ergomed’s PrimeVigilance division, bolstering its market-leading position as a global independent specialist pharmacovigilance provider and establishing a platform for the broader Ergomed services business in the US Combined business expands PrimeVigilance’s geographic coverage in the strategically important US market and strengthens global service offering Acquisition adds over 40 new clients to PrimeVigilance and a strong order book of contracted future revenues of $9.8 million Ashfield Pharmacovigilance Inc. reported $11.6 million revenue and $0.9 million adjusted EBITDA in the year to 30 September 2019 and is expected to be immediately accretive to earnings   London, UK – 13 January 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Compa…

Happy New Year! Here's to a happy, healthy and prosperous 2020 from everyone at PharmiWeb!

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces Syncona Ltd (“Syncona) has made an $80.0 million (£61.1 million)[1] commitment in a Series C financing and has funded the first tranche of this commitment, amounting to $40.0 million (£30.6 million)[2]. This financing augments the previous £88.4 million Series B investment and the £34.8 million Series A investment previously made into Freeline by the founding investors, led by Syncona. The first $40 million tranche will enable Freeline to expand its team, continue to develop its robust manufacturing platform, including commercial supply capability, generate further data in its clinical programmes for Haemophilia B and Fabry Disease, and continue to progress its pip…

The Association of the British Pharmaceutical Industry has launched its General Election 2020 Manifesto for Medicine. The industry body is calling on all parties to ensure that their policies support UK science and research and help maintain the UK’s position as a global leader in medicines and vaccines development into the future. Pharmaceutical companies in the UK collectively employ 63,000 people and invest £4.3 billion in UK R&D – more than any other sector. The ABPI says the next Government should capitalise on the UK’s world-leading life science industry and improve the health of NHS patients by: 1. Prioritising patients and health security in the future UK – EU relationship​ The UK’s membership of the EU has shaped and enforced much of the scientific, regulatory and trade infras…

LONDON – 12 November, 2019 – Charity Parkinson’s UK today announced an international partnership with US-based organisation, The Parkinson’s Foundation who have granted £200,000 towards a potential new therapy for people with Parkinson’s as part of the Parkinson’s Virtual Biotech, led by the charity. Each year, Parkinson’s UK, their supporters and partners invest more than £4 million into the Parkinson’s Virtual Biotech to rapidly develop and test the most promising research findings with the aim of turning them into treatments that will transform the lives of people with Parkinson's. The Parkinson’s Virtual Biotech focuses on the projects that matter the most to the Parkinson’s community and is powered by collaborations with world-leading research organisations that are best placed to del…

A multimillion-pound initiative will bring together hospitals, universities and industry to boost the economy with life sciences innovations. This is the first time that the Northern Health Science Alliance (NHSA) and MedCity have worked collaboratively to support the UK sector’s growth and productivity in this way. Together the two life sciences cluster organisations cover a population of 34 million. MedCity facilitates economic growth in life sciences by working with universities, industry and the NHS within London and the greater south east of England.  The NHSA brings together life sciences expertise in leading universities, NHS Teaching Trusts and Academic Health Science Networks across the North of England. The new partnership will foster economic growth and help speed up the develop…

Manchester’s leading health innovation campus, Citylabs, is set to expand again following high levels of demand as it continues to grow its presence as an international hub for genomics and precision medicine.  Manchester Science Partnerships (MSP) and Manchester University NHS Foundation Trust (MFT) have unveiled plans to develop Citylabs 4.0, a new £35 million development which will grow the existing Citylabs campus by 125,000 sq ft. The Joint Venture partnership between MSP and MFT, the UK's largest NHS provider Trust, is the first of its kind, with the first phase - Citylabs 1.0 - already home to a thriving cluster of diagnostics, medtech, digital health and genomics businesses who are driving the future of medicine and healthcare. The new development represents another step forward fo…

The Primary Care Women’s Health Forum (PCWHF), the leading membership forum for primary care clinicians with an interest in women’s health, is pleased to announce the publication of ‘Her Life Her Health’, its new women’s health publication. It is a new quarterly publication for PCWHF members. Written by primary care clinicians for primary care, the publication follows the journey a woman typically takes throughout her lifetime when accessing healthcare, from contraceptive needs to conception, from menstruation to menopause. Spearheaded by Editor-in-Chief, renowned women’s health expert and Chair of the PCWHF, Dr Anne Connolly, Her Life Her Health combines the latest research and guidelines with news, policy, best practice, features, resources and quick reference guidelines. It is packed wi…

The publication in the Journal of Global Antimicrobial Resistance concluded that application of a nasal gel formulation of XF-73 in healthy volunteers was safe, well tolerated and generated minimal side effects Treatment with XF-73 was also associated with a rapid reduction in nasal Staphylococcus aureus in all subjects; nasal carriage of the bacteria is the source of the majority of post-surgical bacterial infections The same nasal formulation is being used in the Company’s phase 2b trial assessing the microbiological effect of XF-73 on nasal S. aureus in patients scheduled for cardiac surgery and at high risk of postoperative S.aureus/MRSA infection; headline results continue to be expected in mid-2020 Brighton, United Kingdom – 16 October 2019 Destiny Pharma (AIM: DEST), a clinical sta…

Mutational signatures could help improve myeloma patient prognosis Myeloma UK funded research from The Institute of Cancer Research, London, has identified the main biological processes which cause the genetic mutations associated with the development of myeloma. The research, published in Blood Cancer Journal, increases our knowledge of how myeloma develops and evolves and also suggests that analysis of mutational signatures could play a role in helping identify high risk myeloma patients and predicting patient outcomes.  This will aid the development of more personalised treatments for myeloma patients and help to drive improved diagnosis and assessment of prognosis. The team at The Institute of Cancer Research (ICR) analysed whole-genome sequencing (WGS) and whole-exome sequencing (WES)…